# Safety Study of Remsima® (Infliximab) in Rheumatoid Arthritis Patients in Jordan

> **NCT03348046** · — · COMPLETED · sponsor: **Hikma Pharmaceuticals LLC** · enrollment: 22 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Biosimilar Infliximab

## Key facts

- **NCT ID:** NCT03348046
- **Lead sponsor:** Hikma Pharmaceuticals LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-23
- **Primary completion:** 2019-04-14
- **Final completion:** 2019-04-14
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2020-03-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03348046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03348046, "Safety Study of Remsima® (Infliximab) in Rheumatoid Arthritis Patients in Jordan". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03348046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*